Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.

Increased numbers of endothelial cells are observed in peripheral blood of cancer patients. These circulating endothelial cells (CECs) may contribute to the formation of blood vessels in the tumor or reflect vascular damage caused by treatment or tumor growth. Characterization of these cells may aid in the understanding of the angiogenic process and may provide biomarkers for treatment efficacy of angiogenesis inhibitors. To identify markers typical for CECs in cancer patients, we assessed global gene expression profiles of CD146 immunomagnetically enriched CECs from healthy donors and patients with metastatic breast, colorectal, prostate, lung, and renal cancer. From the generated gene profiles, a list of 61 marker genes for CEC detection was generated, and their expression was measured by real-time quantitative PCR in blood samples from 81 metastatic cancer patients and 55 healthy donors that were immunomagnetically enriched for CECs. A set of 34 genes, among which novel CEC-associated genes, such as THBD, BST1, TIE1, POSTN1, SELE, SORT1, and DTR, were identified that were expressed at higher levels in cancer patients compared with healthy donors. Expression of the VWF, DTR, CDH5, TIE, and IGFBP7 genes were found to discriminate between cancer patients and "healthy" donors with a receiver operating characteristic curve accuracy of 0.93. Assessment of the expression of these genes may provide biomarkers to evaluate treatment efficacy.

[1]  J. Soria,et al.  Use of angiogenesis inhibitors in tumour treatment. , 2005, European journal of cancer.

[2]  S. Verma,et al.  Endothelial function testing as a biomarker of vascular disease. , 2003, Circulation.

[3]  N. Bundred,et al.  Surrogate Markers of Tumoral Angiogenesis , 2000, The International journal of biological markers.

[4]  P. Ongusaha,et al.  HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis , 2004, Cancer Research.

[5]  Les Irwig,et al.  Accuracy of diagnostic tests read with and without clinical information: a systematic review. , 2004, JAMA.

[6]  Ryan M. Anderson,et al.  Acquired Expression of Periostin by Human Breast Cancers Promotes Tumor Angiogenesis through Up-Regulation of Vascular Endothelial Growth Factor Receptor 2 Expression , 2004, Molecular and Cellular Biology.

[7]  W. Liang,et al.  9) TM4 Microarray Software Suite , 2006 .

[8]  T. Hudson,et al.  Control genes and variability: absence of ubiquitous reference transcripts in diverse mammalian expression studies. , 2002, Genome research.

[9]  G. Veronesi,et al.  Assessing Tumor Angiogenesis , 2004, Cancer Research.

[10]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[11]  E. Sage,et al.  Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. , 1996, Seminars in cancer biology.

[12]  C. Metz.  Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[13]  H. Mori,et al.  Adrenomedullin: angiogenesis and gene therapy. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.

[14]  S. Reed,et al.  Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. , 2002, Clinical chemistry.

[15]  Shant Kumar,et al.  CD105 is important for angiogenesis: evidence and potential applications , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  G. Pruneri,et al.  Circulating endothelial cells as a novel marker of angiogenesis. , 2003, Advances in experimental medicine and biology.

[17]  A. Bernstein,et al.  Requirement for the TIE family of receptor tyrosine kinases in adult but not fetal hematopoiesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Françoise Dignat-George,et al.  Circulating endothelial cells , 2005, Thrombosis and Haemostasis.

[19]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[20]  W. Aird.  Endothelium as an organ system. , 2004, Critical care medicine.

[21]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[22]  David M. Rocke,et al.  Approximate Variance-stabilizing Transformations for Gene-expression Microarray Data , 2003, Bioinform..

[23]  K. Pienta,et al.  Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.

[24]  R. Lupu,et al.  Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. , 2003, Molecular cancer research : MCR.

[25]  M. Ikeguchi,et al.  Detection of Circulating Cancer Cells After a Gastrectomy for Gastric Cancer , 2004, Surgery Today.

[26]  A. Harris,et al.  A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.